FDA approves expansive label updates for Esperion’s NEXLETOL and NEXLIZET
In a significant advancement for heart health management, Esperion (NASDAQ: ESPR) has announced that the United States Food and Drug Administration (FDA) has approved comprehensive ... Read More
Celltrion USA launches ZYMFENTRA for ulcerative colitis and Crohn’s disease
In a significant advancement for patients with digestive disorders, Celltrion USA has announced the availability of ZYMFENTRA (infliximab-dyyb), marking it as the first and only ... Read More
FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally recognized oncology company, has received approval from ... Read More
FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction in adults with obesity
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk's Wegovy, a milestone in medical advancements aimed at combating ... Read More
Bristol Myers Squibb announces Opdivo FDA approval for urothelial carcinoma
In a significant stride toward enhancing bladder cancer treatment, Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) approval of Opdivo ... Read More
IM Cannabis and Kadimastem announce reverse merger deal
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), known for its significant strides in the medical cannabis sector, has announced a business combination with Kadimastem Ltd, ... Read More